Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 15, 2006

View Archived Issues

Third-generation anti-CD20 antibody shows promise for the treatment of B-cell lymphomas

Phase I/II data show activity of pralatrexate in peripheral T-cell lymphomas

Senicapoc safe, beneficial with long-term treatment in sickle cell disease

AKR-501 increases platelet counts in healthy subjects

Snapshots of recent clinical trials in glioma: Part II

In vitro efficacy of an anti-IGF-1R antibody, AVE-1642, in multiple myeloma

Helix studies topical interferon alpha-2b for anogenital warts

GSK and Epix establish GPCR collaboration

Indevus to acquire Valera

Bifeprunox NDA filed for review

Cell-mediated gene therapy studied for pulmonary arterial hypertension

Schwarz Pharma transfers urology R&D project to 4SC

Phase III study opens in U.S. for Grazax

Biofrontera advances phase IIb/III trial of BF-200 ALA in actinic keratosis

Anyara achieves proof of concept

Genmab announces fully human HuMax-ZP3 antibody program

European orphan drug designation for Sarcodoxome for soft tissue sarcoma

Lilly reviews pipeline progress

Novel treatment options for metabolic disorders described in recent patent literature

New agents for gastrointestinal disorders reported in recent patents

Merck & Co. reviews pipeline status

Biomira reaches SPA for phase III Stimuvax trial

Sanctura XR NDA accepted for review

Tykerb studied as adjuvant treatment in early-stage HER2-positive breast cancer

KRX-0401 begins phase II for rare sarcomas

MicroIslet holds pre-IND meeting for allotransplantation approach in diabetes

Phase II data support once-daily Gabapentin GR in diabetic peripheral neuropathy

Interim safety analysis findings from phase IIb telaprevir HCV study

PI-88 increases disease-free survival by 76% in hepatocellular cancer study

Antagonists of adrenomedullin may be useful to treat bone metastasis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...